[
  {
    "indication": "rinvoq (upadacitinib) for the treatment of inflammatory bowel disease",
    "approval_date": "2025-10-13",
    "year": 2025,
    "confidence": "high",
    "source_text": "FDA Approves Updated Indication Statement for Rinvoq (upadacitinib) for the Treatment of Inflammator"
  },
  {
    "indication": "giant cell arteritis (gca)",
    "approval_date": "2025-04-29",
    "year": 2025,
    "confidence": "high",
    "source_text": "Rinvoq (upadacitinib) Receives U.S. FDA Approval for Giant Cell Arteritis (GCA)"
  },
  {
    "indication": "pediatric patients two years and older with polyarticular juvenile idiopathic arthritis and psoriatic arthritis",
    "approval_date": "2024-06-04",
    "year": 2024,
    "confidence": "high",
    "source_text": "Rinvoq/Rinvoq LQ (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyar"
  },
  {
    "indication": "moderately to severely active crohn's disease in adults",
    "approval_date": "2023-05-19",
    "year": 2023,
    "confidence": "high",
    "source_text": "U.S. FDA Approves Rinvoq (upadacitinib) as a Once-Daily Pill for Moderately to Severely Active Crohn"
  },
  {
    "indication": "adults with active non-radiographic axial spondyloarthritis",
    "approval_date": "2022-10-21",
    "year": 2022,
    "confidence": "high",
    "source_text": "Rinvoq (upadacitinib) Receives FDA Approval for the Treatment of Adults with Active Non-Radiographic"
  },
  {
    "indication": "adults with active ankylosing spondylitis",
    "approval_date": "2022-04-29",
    "year": 2022,
    "confidence": "high",
    "source_text": "Rinvoq (upadacitinib) Approved by U.S. FDA as an Oral Treatment for Adults with Active Ankylosing Sp"
  },
  {
    "indication": "adults with moderately to severely active ulcerative colitis",
    "approval_date": "2022-03-16",
    "year": 2022,
    "confidence": "high",
    "source_text": "Rinvoq (upadacitinib) Receives FDA Approval for the Treatment of Adults with Moderately to Severely "
  },
  {
    "indication": "adults and children 12 years and older with refractory, moderate to severe atopic dermatitis",
    "approval_date": "2022-01-14",
    "year": 2022,
    "confidence": "high",
    "source_text": "U.S. FDA Approves Rinvoq (upadacitinib) to Treat Adults and Children 12 Years and Older with Refract"
  },
  {
    "indication": "active psoriatic arthritis",
    "approval_date": "2021-12-14",
    "year": 2021,
    "confidence": "high",
    "source_text": "Rinvoq (upadacitinib) Receives U.S. FDA Approval for Active Psoriatic Arthritis"
  },
  {
    "indication": "moderate to severe rheumatoid arthritis",
    "approval_date": "2019-08-16",
    "year": 2019,
    "confidence": "high",
    "source_text": "FDA Approves Rinvoq (upadacitinib), an Oral JAK Inhibitor for the Treatment of Moderate to Severe Rh"
  }
]